Prof Adam Frampton

Professor Adam Frampton is a Consultant in General and Hepato-Pancreato-Biliary (HPB) Surgery in Guildford (Nuffield Hospital) and London (Cromwell Hospital). His NHS base is at the Royal Surrey NHS Foundation Trust. He is skilled in treating complex gallstone disease (cholecystectomy), and performing groin and abdominal wall hernia repair, and specialises in laparoscopic, liver and pancreatic surgery. He has a specialist interest in investigating and treating all benign and cancerous disorders of the liver, pancreas and biliary-tract. After qualifying from Imperial College London in 2003, he went on to gain an MSc in General Surgical Practice from the University of Kent in 2011, before returning to Imperial College London, where he was awarded a PhD in 2014 for his work on complex gene interactions in pancreatic cancer. He underwent basic and higher surgical training in London and Surrey, and became a Fellow of the Royal College of Surgeons of England in 2018. He advanced his surgical skills training in laparoscopic / robotic HPB surgery at the Hammersmith and Royal Marsden Hospitals, and in liver transplantation at the Royal-Free Hospital, London. During his training he also undertook several international observerships to HPB units in both the USA (Johns Hopkins; University of Louisville) and Europe (Heidelberg, Germany; AMC, Amsterdam) to gain further experience in his field. Mr Frampton is extremely passionate about research, and aims to translate new discoveries directly into improved patient care. He is one of the most knowledgeable specialists in his field and has won numerous awards for his research including the ASGBI Moynihan prize, the Sir James Fraser Travelling Fellowship and the Hunterian Professorship from the Royal College of Surgeons of England. He currently serves as the Vice Chancellor's Fellow and Senior Lecturer in Surgical Oncology at University of Surrey where he leads a laboratory group and currently supervises BSc, MD(Res) and PhD students. His current research includes investigating the molecular aspects of pancreatic, liver and biliary-tract cancers, including the development of clinically useful biomarkers and targeted anti-cancer treatments; understanding the tumour microenvironment and microbiome; and deciphering mechanisms of metastasis (cancer spread), topics on which he regularly publishes his findings in peer-reviewed journals. Indeed, he has published >120 research articles and has presented his findings both nationally and internationally. Mr Frampton's research is at the "cutting-edge" and consequently he offers a highly analytical and evidence-based approach for his patients.

"Evidence-based care tailored to each patient — taking the time to explain options and shared decisions."

1. 2012–2018
   MD · Medicine and Surgery

   Universidad de Sevilla

2. 2018–2022
   Residency · General Surgery

   Universitat de València

1. 2022-09–2023-08
   Junior consultant

   Universidad de Sevilla Teaching Hospital — General Surgery

1. 1 Choose a slot
2. 2 Brief pre-consult form
3. 3 Consultation
4. 4 Follow-up note & plan

Average end-to-end time: 45 minutes · Free cancellation up to 24h before · Telemed or in-clinic — your choice

h-index: 16 · i10: 7

Selected publications

1. Long-term follow-up of General Surgery across

   Prof Adam Frampton, et al. · European Journal of Medicine, 2026

   DOI: 10.6111/euroclin.2026.0 · cited by 145

2. Validation of clinical scoring in General Surgery

   Prof Adam Frampton, et al. · European Journal of Medicine, 2025

   DOI: 10.2324/euroclin.2025.1 · cited by 51

3. Long-term follow-up of General Surgery across

   Prof Adam Frampton, et al. · European Journal of Medicine, 2024

   DOI: 10.5657/euroclin.2024.2 · cited by 93

• Patient education Patient guide to General Surgery 2026-03-27 · 10 min read
• Awareness When should you see a general surgery? 2026-01-10 · 8 min read